Y
Yingru Zhang
Researcher at Bristol-Myers Squibb
Publications - 34
Citations - 1305
Yingru Zhang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Supercritical fluid chromatography & Bruton's tyrosine kinase. The author has an hindex of 16, co-authored 34 publications receiving 1099 citations.
Papers
More filters
Journal ArticleDOI
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder,Yongmi An,Zhen-Wei Cai,Xiao-Tao Chen,Cheryl M. Clark,Cornelius Lyndon A M,Jun Dai,Johnni Gullo-Brown,Ashok Kumar Gupta,Benjamin J. Henley,John T. Hunt,Robert Jeyaseelan,Amrita Kamath,Kyoung S. Kim,Jonathan Lippy,Louis J. Lombardo,Veeraswamy Manne,Simone Oppenheimer,John S. Sack,Robert J. Schmidt,Guoxiang Shen,Kevin Stefanski,John S. Tokarski,George L. Trainor,Barri Wautlet,Donna D. Wei,David K. Williams,Yingru Zhang,Yueping Zhang,Joseph Fargnoli,Robert M. Borzilleri +30 more
TL;DR: Analogue 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration and has been advanced into phase I clinical trials.
Journal ArticleDOI
Enantioselective chromatography in drug discovery.
TL;DR: Different enantioselective chromatography techniques are reviewed here, with particular emphasis on the most widespread high performance liquid Chromatography (HPLC) and the rapidly emerging supercritical fluid chromatography (SFC) techniques.
Journal ArticleDOI
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
Scott H. Watterson,George V. De Lucca,Qing Shi,Charles M. Langevine,Qingjie Liu,Douglas G. Batt,Myra Beaudoin Bertrand,Hua Gong,Jun Dai,Shiuhang Yip,Peng Li,Dawn Sun,Dauh-Rurng Wu,Chunlei Wang,Yingru Zhang,Sarah C. Traeger,Mark A. Pattoli,Stacey Skala,Lihong Cheng,Mary T. Obermeier,Rodney Vickery,Lorell Discenza,Celia D’Arienzo,Yifan Zhang,Elizabeth M. Heimrich,Kathleen M. Gillooly,Tracy L. Taylor,Claudine Pulicicchio,Kim W. McIntyre,Michael Galella,Andy J. Tebben,Jodi K. Muckelbauer,Chiehying Chang,Richard Rampulla,Arvind Mathur,Luisa Salter-Cid,Joel C. Barrish,Percy H. Carter,Aberra Fura,James R. Burke,Joseph A. Tino +40 more
TL;DR: The structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK are detailed, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities.
Journal ArticleDOI
Capillary Isoelectric Focusing-Mass Spectrometry Method for the Separation and Online Characterization of Intact Monoclonal Antibody Charge Variants
TL;DR: To the best of the authors' knowledge, this is the first time that direct online MS detection and characterization were achieved for mAb charge variants resolved by CIEF as indicated by a well-established linear pH gradient and correlated CIEf-UV charge variant profiles.
Journal ArticleDOI
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.
Ashvinikumar V. Gavai,Claude A. Quesnelle,Derek J. Norris,Wen-Ching Han,Patrice Gill,Weifang Shan,Aaron Balog,Ke Chen,Andrew J. Tebben,Richard Rampulla,Dauh-Rurng Wu,Yingru Zhang,Arvind Mathur,Ronald E. White,Anne Rose,Haiqing Wang,Zheng Yang,Asoka Ranasinghe,Celia D’Arienzo,Victor R. Guarino,Lan Xiao,Ching Su,Gerry Everlof,Vinod Arora,Ding Ren Shen,Mary Ellen Cvijic,Krista Menard,Mei-Li Wen,Jere E. Meredith,George L. Trainor,Louis J. Lombardo,Richard E. Olson,Phil S. Baran,John T. Hunt,Gregory D. Vite,Bruce S. Fischer,Richard A. Westhouse,Francis Y. Lee +37 more
TL;DR: Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors selected as a candidate for clinical evaluation.